Child Bipolar Network Ketogenic Diet Approach to Bipolar Disorder in Adolescents

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT06920940
Status
Recruiting

Conditions

  • Adolescents
  • Bipolar Disorder (BD)
  • Bipolar Disorder I or II
  • Bipolar Disorder NOS
  • Bipolar Spectrum Disorder

Eligibility Criteria

Sex
ALL
Age
12 Years - 21 Years
Healthy Volunteers
Not accepted

Interventions

  • Ketogenic Therapy — OTHER
    During the keto therapy (16 weeks), the youth will participate in a strict ketogenic diet, with adjustments made as necessary from weekly dietitian coaching sessions.

Study Details

The present study is an open trial of ketogenic diets for adolescents and young adults (ages 12-21 yrs) in the depressive or mixed phases of bipolar disorder (BD). The investigators aim to determine whether combining standard of care pharmacological treatment for bipolar spectrum disorders with a 16-week ketogenic diet is well-tolerated and associated with improvements in depression, inflammatory and metabolic indicators, and executive functioning over the study period. The experimental treatment in this study is a 16-week full ketogenic diet. Four study sites (UCLA, U Cincinnati, U Colorado and U Pittsburgh) will recruit 80 total youth (20 each) from bipolar specialty clinics. All youth eligible for the ketogenic therapy will be provided with the ketogenic diet and standard of care pharmacological treatment. During the diet therapy youth will be seen by a study child/adolescent psychiatrist at least once a month (and more frequently when needed), with the psychiatrist recommending and providing side effects monitoring and pharmacotherapy as clinically indicated. The youth and caregivers will also meet with an expert dietitian who will coach all youth on maintaining the ketogenic diet (low carbs, high fats, medium protein) and making sure the child is tolerating the diet and getting enough liquid and nutrients, following the practice guidelines of the International Ketogenic Diet Study Group for treating youth. All youth and involved caregivers will also be provided will at least one motivational enhancement session to support them in goal setting and completion of the study elements. Throughout the study the investigators will assess metabolic (e.g., blood ketones, HOMA-IR) and inflammatory indicators (e.g., C-reactive protein), both for safety reasons and to assess correlates of symptomatic change. Independent evaluators will assess youth every month regarding their symptoms (depression, mania, anxiety, psychosis), psychosocial functioning, and quality of life. The investigators anticipate that the pilot will transpire over 24 months and be an important step toward establishing feasibility and acceptability of ketogenic therapy for this population, not only in terms of diet administration and compliance but also for obtaining symptomatic, metabolic and inflammatory measurements.

Key Dates

Start date
Mar 19, 2025
Status verified
Apr 2026
Primary completion
Mar 19, 2027
Completion
Mar 19, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ketogenic Therapy for Bipolar Spectrum Disorders
    This is a pilot trial with one intervention arm. All youth meeting eligibility for the ketogenic therapy phase of this pilot trial will be invited to participate in the intervention and progress tracking.

Primary Outcome Measure

Diet Adherence [ Time Frame: From initiation of ketogenic therapy to the end of treatment (up to 16 weeks) ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
UCLA Semel Institute Max Gray Child and Adolescent Mood Disorders Program (CHAMP)Los AngelesCalifornia90024
Shelby Grody, B.A.
310-906-0917
Megan C Ichinose, Ph.D.
310-267-0170
David J Miklowitz, Ph.D. (PRINCIPAL_INVESTIGATOR)
Danielle M Denenny, Ph.D. (SUB_INVESTIGATOR)
Megan C Ichinose, Ph.D. (SUB_INVESTIGATOR)
Elizabeth A Horstmann, M.D. (SUB_INVESTIGATOR)
Patricia D Walshaw, Ph.D. (SUB_INVESTIGATOR)
Madeline O Jansen, M.D. (SUB_INVESTIGATOR)
University of Colorado Denver, Anschutz Medical CampusAuroraColorado80045
Emerald Saldyt
303-724-5350
Christopher Schneck, M.D. (PRINCIPAL_INVESTIGATOR)
Melissa Batt, M.D. (SUB_INVESTIGATOR)
Aimee Sullivan, Ph.D. (SUB_INVESTIGATOR)
University of Cincinnati College of MedicineCincinnatiOhio45267
Cathy Bailey
513-558-4731
Melissa Delbello, M.D. (PRINCIPAL_INVESTIGATOR)
Rodrigo Patino Duran, M.D. (SUB_INVESTIGATOR)
University of Pittsburgh School of MedicinePittsburghPennsylvania15213
Ada Lopaczynski
412-770-7396
Mary Kay Gill, MSN, RN
412-463-0108
Danella Hafeman, M.D. (PRINCIPAL_INVESTIGATOR)
Boris Birmaher, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

Related Studies